Quarterly ResultAug 6, 2026, 06:11 AM
LifeStance Q2 Revenue $435.4M, Net Income $23.6M; $100M Buyback
AI Summary
LifeStance Health Group reported strong second-quarter 2026 financial results, with revenue increasing 26% to $435.4 million and net income reaching $23.6 million, a significant improvement from a net loss in the prior year. The company also announced a new $100 million share repurchase program, replacing a previous one. Based on this performance, LifeStance raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA.
Key Highlights
- Board approved a new $100 million share repurchase program.
- Q2 2026 revenue increased 26% year-over-year to $435.4 million.
- Q2 2026 net income was $23.6 million, compared to a $3.8 million net loss in Q2 2025.
- Q2 2026 Adjusted EBITDA grew 94% year-over-year to $66.0 million.
- Full-year 2026 revenue guidance raised to $1.685 billion to $1.725 billion.
- Full-year 2026 Adjusted EBITDA guidance raised to $215 million to $235 million.
- Clinician base grew 11% to 8,542; visit volumes rose 19% to 2.6 million.
- Generated $87.9 million in free cash flow during the second quarter.
Price Impact
More from LFST